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Summary. We studied 57 childhood acute lymphoblastic
leukaemia (ALL) patients who remained in continuous
complete remission after treatment according to the Dutch
Childhood Leukaemia Study Group ALL-8 protocols. The
patients were monitored at 18 time points during and after
treatment [640 bone marrow (BM) and 600 blood samples]
by use of cytomorphology and immunophenotyping for the
expression of TdT, CD34, CD10 and CD19. Additionally, 60
BM follow-up samples from six patients were subjected to
clonality assessment via heteroduplex polymerase chain
reaction (PCR) analysis of immunoglobulin Vh-Jh gene
rearrangements. We observed substantial expansions of
normal precursor B cells in regenerating BM not only after
maintenance therapy but also during treatment. At the end
of the 2-week intervals after consolidation and reinduction
treatment, B-cell-lineage regeneration was observed in BM
with a large fraction of immature CD341/TdT1 B cells. In
contrast, in regenerating BM after cessation of maintenance
treatment, the more mature CD191/CD101 B cells were
significantly increased, but the fraction of immature
CD341/TdT1 B cells was essentially smaller. Blood samples
showed a profound B-cell lymphopenia during treatment
followed by a rapid normalization of blood B cells after
treatment, with a substantial CD101 fraction (10±30%).
Heteroduplex PCR analysis confirmed the polyclonal origin
of the expanded precursor B cells in regenerating BM. This
information regarding the regeneration of BM is essential
for the correct interpretation of minimal residual disease
studies.
Keywords: ALL, regenerating bone marrow, B-cell precur-
sors, immunophenotyping, minimal residual disease.
The lymphoid compartment of bone marrow (BM) in
healthy individuals contains a small fraction of early B-
lineage cells with immature lymphoblastic morphology or,
more frequently, with more mature cytomorphological
lymphocytic characteristics (Muehleck et al, 1983; Longacre
et al, 1989). These cells exhibit a precursor B-cell
immunophenotype with expression of TdT, CD10 and
CD34 in addition to B-lineage markers such as CD19,
CD22 and/or CD79a (Janossy et al, 1979; Greaves et al,
1983; Loken et al, 1987; Hurwitz et al, 1992; Dworzak et al,
1998a). The proportion of such cells in children can be
quite marked, ranging from 5% to 15% of mononuclear
cells (MNCs) in BM aspirates, and the number of early B-cell
precursors progressively decreased with age in children
(Caldwell et al, 1991; Rego et al, 1998; Lucio et al, 1999).
Apparently, 80±85% of children with acute lymphoblas-
tic leukaemia (ALL) have an early B-cell phenotype. These
precursor B-ALL are generally regarded as malignant
counterparts of immature precursor B cells in BM. The
standard procedure for evaluating the results of treatment
in ALL is cytomorphological analysis of BM and peripheral
blood (PB) smears. When less than 5% of blasts are present
upon this investigation, a complete remission of disease is
assumed. But by cytomorphology alone, it is virtually
impossible to distinguish between normal haematopoietic
precursors or residual leukaemic cells (Van Dongen et al,
1996; Coustan-Smith et al, 1998). Distinction between
normal and malignant cells is particularly important for
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regenerating BM in precursor B-ALL cases because the
levels of committed B-cell progenitors (TdT1 or TdT2) were
anecdotally reported to be as high as 50% of MNCs in BM
samples after treatment (Borella et al, 1972; Smedmyr et al,
1991; Fukushima et al, 1998).
Most reports on regenerating BM after chemotherapy in
ALL are based on small patient groups and concern single
time points (Kluin-Nelemans et al, 1986; Van den Doel et al,
1988; Smedmyr et al, 1991; Duval et al, 1997; Fukushima
et al, 1998). To assess the normal frequencies of precursor
B-cells in PB and BM during and after treatment and the
potential interference of these cells with the detection of
minimal residual disease (MRD), a study by morphological
and immunological methods was started in 1991. We report
the follow-up results of 57 precursor B-ALL patients in
continuous complete remission (CCR) with a median follow-
up time of 5 years. Significantly increased frequencies of
morphologically suspicious cells with precursor B-cell
immunophenotype were not only found after treatment
but also during the initial treatment phases at the end of 2-
week intervals in therapy. We applied heteroduplex poly-
merase chain reaction (PCR) analysis of immunoglobulin
heavy chain (IGH) gene rearrangements in order to exclude
the presence of a clonal malignant precursor B-cell
population at the time of BM regeneration.
MATERIALS AND METHODS
Patients. The study group consisted of 57 ALL patients
aged 0±16 years (0±5 years n  42; 6±16 years n  15).
They were treated according to the Dutch Childhood
Leukaemia Study Group (DCLSG) ALL-8 protocol (intake
period of the 57 patients was 1991±95), which had a BFM
(Berlin±Frankfurt±MuÈ nster) backbone. The patients were
stratified into three branches: standard risk group (SRG),
medium risk group (MRG) and high-risk group (HRG),
mainly according to the leukaemic cell mass (risk factor; RF)
and the treatment response (Reiter et al, 1994). Only SRG
and MRG patients with precursor B-ALL were considered for
this study. SRG: , 1´0  109/l PB blasts on day 8,
RF , 0´8, no central nervous system (CNS) disease, no
mediastinal mass, no T-ALL. MRG: , 1´0  109/l PB blasts
on day 8, RF $ 0´8, or RF , 0´8 and CNS disease and/or
presence of a mediastinal mass and/or T-ALL.
The first part of the induction protocol was identical for
all patients. For SRG patients, the induction protocol was
directly followed by the consolidation protocol. MRG
patients received a 4-week longer induction treatment and
continued with the consolidation protocol, after a 2-week
break in therapy. After the consolidation protocol, all
patients (SRG and MRG) had a 2-week interval before
starting the reinduction treatment and another 2-week
interval before entering maintenance therapy. Therapy
ended 2 years after diagnosis. All 57 children subjected to
the study were in continuous complete remission with a
median follow-up time of 5 years. The median observation
time by use of cytomorphology and immunophenotyping
was 179 weeks for the SRG patients (n  23) and
173 weeks for the MRG (n  34) patients.
Cell samples. BM and PB samples of Dutch children with
ALL were sent to the central laboratory of the DCLSG for
confirmation and classification of diagnosis. Samples were
sent by express mail and processed within 24 h of collection.
If the diagnosis of ALL was confirmed and sufficient cells
were available, the patients were followed at 18 well-defined
time points (T1 to T18; see Fig 1) during and after
treatment by use of cytomorphology and immunophenotyp-
ing. A total of 640 BM samples (243 SRG and 397 MRG)
and 600 PB samples (227 SRG and 373 MRG) from the 57
ALL patients were analysed by these techniques. Relapsed
patients were excluded from the current study. All pro-
cedures were performed according to the local guidelines of
the Medical Ethics Committees and samples were obtained
after informed consent.
Cytomorphology. BM and PB smears at diagnosis and
during follow-up were stained by standard techniques,
including May±GruÈ nwald±Giemsa (all time points) and
periodic acid±Schiff reagents, Sudan black B, myeloperoxi-
dase, a combined naphthol AS-D chloroacetate esterase and
a-naphthylacetate esterase (only at diagnosis).
Immunophenotyping. MNCs were isolated from BM and PB
by Ficoll±Paque centrifugation (density 1´077 g/cm3;
Pharmacia, Uppsala, Sweden) and washed three times.
Washing of cells was performed with phosphate-buffered
saline supplemented with 1% bovine serum albumin (PBS/
BSA 1%, pH 7´8). Erythrocytes were lysed if necessary by
0´83% ammonium chloride. The viability was assessed by
trypan blue dye exclusion and was . 85% in all samples
studied. The following monoclonal antibodies (mAbs) were
used: CD10 (J5) and CD19 (B4) from Beckman Coulter
Corporation (Fullerton, CA, USA); CD34 from Becton
Dickinson (San Jose, CA, USA); and rabbit anti-TdT
antiserum from Supertechs (Bethesda, MD, USA).
Fig 1. Median percentages of TdT1, CD101, CD191 and CD341
cells during chemotherapy (sampling points 1±10) and after
treatment cessation (sampling points 11±18) for childhood ALL
patients treated according to the MRG schedule of the DCLSG ALL-8
protocol. After a relatively short pause of 2 weeks during initial
treatment (points 2 and 3), an increase of both immature and more
mature B-cell precursor subsets is observed. After completion of
treatment, a major expansion of more mature CD101/CD191 cells
is observed, whereas percentages of immature CD341 and TdT1
cells show a minor increase (2±6%). I, induction; M, consolidation;
II, reinduction; maintenance-Rx, maintenance treatment.
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For flow cytometric immunophenotyping, the concentra-
tion of MNC suspension was adjusted to 107/ml. For single
labelling with CD10 and CD19, a two-step procedure was
used. Therefore, 50 ml of MNC suspension was incubated
(48C, 30 min) with 50 ml of the relevant mAb, washed and
subsequently incubated with 50 ml of fluorescein isothio-
cyanate (FITC)-conjugated goat anti-mouse immunoglobu-
lin (Ig) antiserum (48C, 30 min) and washed again. CD34
was used as a phycoerythrin (PE)-conjugated mAb in a one-
step procedure. After labelling, a total of 15 000 cells were
acquired and analysed on a FACScan flow cytometer using
lysys ii software (Becton Dickinson). Gating was set on
forward- (FCS) and side-scatter (SSC) parameters to exclude
cellular debris. The frequency of the cells expressing the
relevant marker was calculated as a percentage of MNCs
analysed.
Cytocentrifuge preparations were made with a cell
concentration of 106/ml (50 ml per preparation), fixed in
methanol (48C, 30 min), washed, incubated with 15 ml
rabbit anti-TdT antiserum in a moist chamber (room
temperature, 30 min), washed, subsequently incubated
with 15 ml FITC-conjugated goat anti-rabbit Ig antiserum
and washed again. For double TdT and CD10 detection,
MNCs in suspension were labelled with CD10 and a
tetramethylrhodamine isothiocyanate (TRITC)-conjugated
goat anti-mouse Ig antiserum. The labelled cells were spun
onto slides, fixed and subjected to TdT staining. All
preparations were mounted in glycerol with 1 mg p-
phenylenediamine/ml and analysed on a Zeiss fluorescence
microscope equipped with phase contrast facilities (Zeiss,
Oberkochen, Germany) (Van Dongen et al, 1987). At least
200 TdT-positive cells were analysed for expression of the
relevant markers. If less than 200 TdT-positive cells were
present, the whole slide was screened.
Southern blot analysis. DNA samples from precursor B-ALL
patients were subjected to molecular analysis of the IGH
gene. DNA was isolated from fresh or frozen MNC fractions
as described previously (Van Dongen & Wolvers-Tettero,
1991). Fifteen micrograms of DNA was digested with BglII
or BamHI±HindIII restriction enzymes (Pharmacia), size
separated in 0´7% agarose gels and transferred to Nytran-
13N nylon membranes (Schleicher and Schuell, Dassel,
Germany) and IGH gene configuration was analysed by
hybridization of the filters with the IGHJ6 probe (Dako
Corporation, Carpinteria, CA, USA) ( Van Dongen &
Wolvers-Tettero, 1991; Beishuizen et al, 1993).
PCR amplification. PCR amplification of complete IGH gene
rearrangements was essentially performed as described
previously (Pongers-Willemse et al, 1999; SzczepanÂ ski et al,
1999a). For identification of clonal vh-jh rearrangements at
diagnosis, 0´1 mg DNA, 12´5 pmol of the 5 0 and 3 0 primers
and 1 U Taq polymerase (PE Biosystems, Foster City, CA,
USA) were used in a 100-ml PCR reaction. For analysis of
follow-up samples, 1 mg DNA, 30 pmol of the 5 0 and 3 0
oligonucleotide primers and 2´5 U TaqGold polymerase (PE
Biosystems) were used in a 100-ml PCR reaction. DNA
dilutions of diagnostic BM in polyclonal MNCs were
amplified in parallel to determine the sensitivity of the
assay. All primers were synthesized on an ABI 392 DNA
synthesiser (PE Biosystems) using the solid phase phospho-
triester method. PCR conditions after an initial 10-min step
of denaturation and TaqGold polymerase activation com-
prised: 45 s at 928C, 90 s at 608C and 2 min at 728C for 40
cycles using a Perkin-Elmer thermal cycler (PE Biosystems).
After the last cycle, an additional extension step of 10 min
at 728C was performed. Appropriate positive and negative
controls were included.
Heteroduplex analysis of PCR products. For heteroduplex
analysis, the PCR products were denatured at 948C for
5 min after the final cycle of amplification and subsequently
cooled to 48C for 60 min to induce duplex formation
(Langerak et al, 1997; SzczepanÂ ski et al, 1998). After duplex
formation, the hetero- and/or homoduplexes were immedi-
ately loaded on 6% non-denaturing polyacrylamide gels in
0´5 Tris/boric acid/EDTA (TBE) buffer, run at room
temperature and visualized by ethidium bromide staining.
A 100-bp DNA ladder (Promega Corporation, Madison, WI,
USA) was used as size marker.
RESULTS
BM B-cell precursors during ALL treatment
Until day 33 of the induction treatment, all patients received
the same therapy. At this time (T1) the induction response
of all patients was evaluated. SRG and MRG patients were
found to have similarly low frequencies (0´3±2%) of cells
positive for TdT, CD34, CD10 and somewhat higher
percentages of CD191 cells (, 7%) (Table I and Fig 1).
After this time point, SRG patients immediately entered
the consolidation treatment and were evaluated at T3, just
before the reinduction treatment, and again at T4, just
before starting maintenance treatment. Both samples were
taken after a 2-week break in the treatment. At T3, a rise in
cells positive for TdT (mean 3´9 ^ 2´6%), CD34 (mean
4´6 ^ 4%), CD10 (mean 8´0 ^ 7´2%) and CD19 (mean
9´6 ^ 7´4%) was observed compared with T1. At T4, these
percentages were still higher than at the end of the
induction phase (T1).
In contrast to SRG patients, MRG patients had a 2-week
interval in treatment after longer induction therapy. The
results of this phase were evaluated at T2. Compared with
SRG patients at T3 and T4, an even higher rise in cells
positive for TdT (mean 9´5 ^ 6´9%), CD34 (mean
12´5 ^ 7´2%), CD10 (mean 13´0 ^ 9´4%) and CD19
(mean 12´4 ^ 9´2%) was found at T2 in MRG patients
(Table I).
During maintenance treatment (T5 to T10), the frequen-
cies of cells positive for CD19, CD10, TdT and CD34 were
similarly low (1±5%) in the SRG and MRG patients.
BM B-cell precursors after treatment cessation
The first post-treatment BM sample evaluation was taken at
T11, i.e. about 3 months after stopping chemotherapy. At
that time point, the CD101 and CD191 cells were found in
high percentages, i.e. 29´9 ^ 15´6% and 31´6 ^ 15´9%,
respectively, for SRG patients. Only minor differences were
found between SRG and MRG patients (Table I and Fig 1).
Although CD341 (mean 5´7 ^ 2´6%) and CD101/TdT1
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Table I. Percentages of MNCs expressing TdT, CD10, CD34 and CD19 in BM during and after chemotherapy for children with ALL in the MRG (n  34).
Sampling
time point*
Average time from
diagnosis (weeks)
Number of patients
analysed
Morphological blasts
(mean ^ SD)
% of CD341
(mean ^ SD)
% of TdT1
(mean ^ SD)
% of CD101
(mean ^ SD)
% of TdT1/CD101
(mean ^ SD)
% of CD191
(mean ^ SD)
T1 5 30 0´7 ^ 0´7 1´7 ^ 2´1 0´5 ^ 1´0 0´9 ^ 3´0 0´1 ^ 0´3 7´2 ^ 5´5
T2 14 27 2´1 ^ 1´4 12´5 ^ 7´2 9´5 ^ 6´9 13´0 ^ 9´4 8´0 ^ 6´1 12´4 ^ 9´2
T3 24 31 2´0 ^ 1´4 8´2 ^ 6´0 6´6 ^ 4´4 19´1 ^ 12´7 5´6 ^ 4´4 18´1 ^ 12´1
T4 34 32 1´8 ^ 1´4 6´1 ^ 4´6 4´6 ^ 4´2 7´2 ^ 9´1 3´4 ^ 3´7 7´4 ^ 9´3
T5 46 22 0´6 ^ 0´5 2´7 ^ 2´1 1´3 ^ 1´2 1´8 ^ 5´9 0´6 ^ 1´1 2´2 ^ 5´7
T6 59 26 0´7 ^ 0´7 3´9 ^ 2´4 1´7 ^ 1´4 1´7 ^ 4´0 0´6 ^ 0´8 1´8 ^ 2´0
T7 72 27 0´8 ^ 0´8 3´3 ^ 2´3 1´1 ^ 1´0 1´2 ^ 1´9 0´7 ^ 1´7 1´8 ^ 1´9
T8 84 27 0´9 ^ 0´7 3´5 ^ 2´2 1´4 ^ 1´3 3´2 ^ 8´4 0´7 ^ 1´0 4´2 ^ 7´5
T9 94 11 0´7 ^ 0´6 3´4 ^ 2´5 1´0 ^ 0´8 0´9 ^ 1´2 0´2 ^ 0´3 1´7 ^ 1´2
T10 102 26 1´0 ^ 0´7 3´5 ^ 5´7 1´5 ^ 1´3 2´0 ^ 8´9 0´6 ^ 0´9 3´2 ^ 7´7
T11 116 27 1´3 ^ 0´7 4´4 ^ 3´0 3´0 ^ 2´2 29´9 ^ 15´6 3´0 ^ 1´7 31´6 ^ 15´9
T12 130 21 1´0 ^ 0´7 4´6 ^ 1´9 4´1 ^ 3´6 23´8 ^ 11´3 3´4 ^ 3´1 27´6 ^ 10´4
T13 143 22 1´3 ^ 0´6 4´6 ^ 2´0 3´0 ^ 1´7 21´4 ^ 13´5 2´8 ^ 1´6 26´4 ^ 13´8
T14 157 24 1´1 ^ 0´6 4´4 ^ 1´4 2´8 ^ 2´1 18´9 ^ 9´5 2´5 ^ 1´9 25´4 ^ 11´2
T15 168 17 1´1 ^ 0´7 4´9 ^ 2´1 3´1 ^ 1´2 22´7 ^ 12´5 2´9 ^ 1´2 28´6 ^ 10´5
T16 181 15 0´9 ^ 0´6 4´1 ^ 2´3 2´4 ^ 1´6 15´4 ^ 9´0 2´3 ^ 1´6 22´1 ^ 8´6
T17 195 6 1´3 ^ 1´3 3´3 ^ 2´1 2´6 ^ 1´4 20´2 ^ 11´1 2´3 ^ 1´2 26´3 ^ 11´5
T18 207 6 1´3 ^ 0´5 4´5 ^ 1´4 3´2 ^ 1´6 23´6 ^ 12´8 3´1 ^ 1´5 27´4 ^ 13´0
*See Fig 1 for relation to treatment phase.
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cells (mean 3´8 ^ 2´1%) also slightly increased after
treatment cessation, these frequencies were now signifi-
cantly lower than the frequencies of CD191 or CD101 cells
(Table I). The high values for CD191 and CD101 precursor
B cells were consistently found at all later time points, at
least until 2 years after stopping the therapy.
PB B-cell precursors during ALL treatment and after treatment
cessation
The mean frequencies of PB CD191 cells were persistently
low throughout consolidation, reinduction and mainten-
ance treatment phases, ranging from 1% to 5% of MNCs.
Moreover, the most immature TdT1/CD101 B-cell precur-
sors were absent or very low (, 0´1%) in PB throughout
the different treatment phases as well as after treatment
cessation (Table II). After chemotherapy cessation, the per-
centages of PB B cells rapidly increased to normal values; at
T11, CD191 cells already comprised 15´9 ^ 7´4% in MRG
patients. Interestingly, a substantial proportion (10±30%) of
these CD191 cells (2±5% of PB MNCs) was co-expressing
the CD10 molecule. The differences between SRG and MRG
patients were not significant.
Southern blotting and heteroduplex PCR analysis
Southern blotting of diagnosis DNA from six patients (three
SRG and three MRG) revealed clonal IGH gene rearrange-
ments in all cases. Heteroduplex PCR analysis showed a
single monoclonal Vh-Jh product in five patients and two
homo- and heteroduplexes in one patient, indicating
biallelic IGH gene rearrangements (Langerak et al, 1997;
SzczepanÂ ski et al, 1998). The sensitivity of heteroduplex
PCR analysis for these clonal markers ranged from 1% to
5%. A total of 60 BM follow-up samples were analysed, 10
per patient on average. None of the follow-up samples
contained monoclonal PCR-detectable complete IGH gene
rearrangements identical to those found at diagnosis. The
intensity of heteroduplex smears derived from polyclonal B
cells correlated with the percentages of B-lineage cells in
the sample (Fig 2).
Fig 2. Malignant lymphoblasts at diagnosis contained a mono-
clonal Vh1-Jh gene rearrangement, as demonstrated by hetero-
duplex PCR analysis. Dilution of the diagnosis BM DNA into
polyclonal MNC DNA derived from healthy blood donors showed a
sensitivity threshold of approximately 1%. None of the follow-up
samples contained clonal homoduplexes. The density of hetero-
duplex smears is related to the percentages of polyclonal CD191
cells in the analysed samples. he, heteroduplexes; ho, homodu-
plexes; Mw marker, 100-bp molecular weight marker.
Table II. Percentages of MNCs expressing TdT, CD10 and CD19 in PB for children with ALL in the MRG (n  34).
Sampling
time point*
Average time from
diagnosis (weeks)
Number of
patients analysed
% of TdT1
(mean ^ SD)
% of CD101
(mean ^ SD)
% of CD191
(mean ^ SD)
T1 5 28 0´3 ^ 0´9 0 ^ 0´2 8´6 ^ 5´5
T2 14 25 0´3 ^ 0´4 0´2 ^ 0´5 1´2 ^ 1´4
T3 24 30 0´1 ^ 0´2 0´3 ^ 0´6 3´2 ^ 2´9
T4 34 31 0´1 ^ 0´2 0´2 ^ 0´4 0´8 ^ 0´9
T5 46 22 0´1 ^ 0´1 0´1 ^ 0´3 1´3 ^ 1´9
T6 59 23 0´1 ^ 0´2 0´1 ^ 0´4 2´4 ^ 3´4
T7 72 25 0´1 ^ 0´3 0´3 ^ 0´8 1´8 ^ 1´9
T8 84 27 0 ^ 0´1 1´6 ^ 4´9 3´7 ^ 5´1
T9 94 10 0 ^ 0´1 0´2 ^ 0´4 1´6 ^ 1´6
T10 102 23 0´1 ^ 0´5 0´3 ^ 0´7 3´0 ^ 1´8
T11 116 27 0´1 ^ 0´3 4´8 ^ 4´4 15´9 ^ 7´4
T12 130 20 0´2 ^ 0´7 4´7 ^ 7´1 21´1 ^ 6´8
T13 143 19 0´1 ^ 0´1 5´1 ^ 7´8 21´3 ^ 8´4
T14 157 23 0 ^ 0´1 3´8 ^ 4´5 21´1 ^ 8´6
T15 168 15 0´1 ^ 0´3 3´2 ^ 3´8 21´5 ^ 15´3
T16 181 14 0 ^ 0´1 3´5 ^ 4´6 18´3 ^ 5´5
T17 195 6 0 2´2 ^ 2´6 23´5 ^ 14´5
T18 207 5 0´3 ^ 0´4 1´9 ^ 2´1 21´8 ^ 5´8
*See Fig 1 for relation to treatment phase.
q 2000 Blackwell Science Ltd, British Journal of Haematology 110: 139±146
Regeneration of Normal B-cell Precursors in ALL 143
DISCUSSION
The BM MNC compartment of healthy individuals contains
a subset of precursor B cells characterized by the expression
of markers such as CD19, CD10, TdT and CD34 (Janossy
et al, 1979; Greaves et al, 1983; Loken et al, 1987). Such
cells constitute 5±15% of MNCs in BM aspirates from
healthy children. Increases in the proportion of normal B-
cell precursors have been reported in children with benign
diseases (Longacre et al, 1989; Fukushima et al, 1998). Even
the immature CD101/TdT1 cells can occur in unusually
high frequencies and may raise suspicion for malignancy,
particularly in BM regenerating after chemotherapy (Smed-
myr et al, 1991; Duval et al, 1997; Dworzak et al, 1997;
Fukushima et al, 1998).
Our study of 640 BM samples and 600 PB samples from a
homogeneous large group of 57 precursor B-ALL patients
demonstrated that even after a relatively short pause of
2 weeks during treatment regeneration of suppressed B-cell
development takes place. After such short breaks in
treatment, particularly immature CD101/TdT1 and
CD341 cells can be found in BM at frequencies as high as
20% of MNCs. The type and extent of B-cell regeneration
seems to be proportional to the aggressiveness of preceding
treatment, as was shown by the differences in marker
positivity between the two treatment arms. For example, at
T3 in SRG patients, the immature TdT1 cells comprised
3´9 ^ 2´6% of MNCs, but in MRG patients 6´6 ^ 4´4% of
MNCs. Similar differences appeared to be present for CD341,
CD191 and TdT1/CD101 cells.
After cessation of maintenance chemotherapy, we
observed bulky polyclonal recovery of precursor B cells in
BM. Three months after treatment withdrawal, the B-cell
compartment markedly increased from approximately 5% to
approximately 30% of BM MNCs (Table I and Fig 1). The
detected frequencies of around 30% (^ 16%) of BM MNCs
for CD101 and CD191 cells were significantly higher than
those found in healthy donors (5±15% of BM MNCs)
(Caldwell et al, 1991; Rego et al, 1998). It is not surprising
to see such massive B-cell regeneration after chemotherapy
for ALL bearing in mind that this type of treatment is
accompanied by profound B-cell lymphopenia, which was
also clearly demonstrated in this study. This is in contrast to
T-cell numbers and T-cell immunophenotype in PB, which
remained virtually normal (Caver et al, 1998). Moreover,
long-term survivors of ALL have been shown to lack
protective antibody levels specific for common paediatric
bacterial or viral pathogens, despite prior vaccinations
(Smith et al, 1995). Among regenerating B-cell progenitors
in BM after maintenance chemotherapy, we observed an
obvious predominance of the more mature CD191/CD101/
TdT2/CD342 population, which is also predominant in the
normal paediatric BM B-lineage cells (Lucio et al, 1999).
Furthermore, we and colleagues (Fukushima et al, 1998)
found that the decline to normal percentages of CD101 and
CD191 BM cells did not occur within 2 years from stopping
the chemotherapy (T18).
We observed a rapid normalization of the blood B-cell
counts after treatment cessation. However, a substantial
subset of these CD191 cells (10±30%) was co-expressing
CD10, which is markedly higher than normal PB, where
CD191/CD101 cells comprise less than 1% of MNCs (Ryan
et al, 1984; Calado et al, 1999). This more mature CD191/
CD101/TdT2 precursor B-cell population apparently reflects
the massive regeneration in BM at this time point and may
be perceived as the release of this more mature precursor
B-cell subset into the blood during the first 2 years after
treatment (Table II). Apparently, the interaction between
stromal cells and more mature CD191/CD101/TdT2 pre-
cursor B cells in regenerating BM is less stringent than in
immature CD191/CD101/TdT1 B-cell precursors because
this subset was hardly found in the PB. This also implies
that the finding of an immature CD191/CD101/TdT1 B-cell
subset in PB of ALL patients is very suggestive of ALL cells.
The presence of early B-cell precursors in normal BM as
well as their polyclonal expansion in `regenerating' BM
should be taken into account when immunophenotypic
MRD studies are performed in precursor B-ALL. On one
hand, moderately increased frequencies of CD191/CD101/
TdT1 BM cells should never be directly interpreted as
relapse of ALL, particularly during the high-dose treatment
phases. On the other hand, substantial increase in B-cell
precursors after chemotherapy, particularly with a homo-
genous immunophenotype, may herald a relapse of the
disease (Farahat et al, 1995; Vervoordeldonk et al, 1996;
Griesinger et al, 1999). Alternatively, malignant cells in
precursor B-ALL patients can be distinguished from normal
early B-lineage cells based on atypical immunological
characteristics. This concerns tumour-associated ectopic
expression of antigens such as TdT, CD66c or NG2, cross-
lineage antigen expression, maturational asynchronous
antigen expression, antigen overexpression or loss of
markers expressed in normal B-cell precursors (Van Dongen
et al, 1996; Dworzak et al, 1998b; Ciudad et al, 1999; Sugita
et al, 1999). Such characteristics can be detected with
currently available four-colour flow cytometry in at least
85% of the cases (Wells et al, 1998; Campana & Coustan-
Smith, 1999; Lucio et al, 1999; Weir et al, 1999).
In problematic cases, molecular studies are warranted to
ensure that B-lineage cells really represent regenerating
normal BM precursors and are not the first sign of an
imminent relapse. For this purpose, we applied heteroduplex
PCR analysis, which we routinely use for identification of
clonal Ig and TCR gene rearrangements as MRD targets
(Langerak et al, 1997; SzczepanÂ ski et al, 1998, 1999b).
Heteroduplex PCR analysis of IGH gene rearrangements in a
total of 60 remission BM follow-up samples demonstrated
that B-cell precursors in regenerating BM indeed had a
polyclonal origin. Furthermore, the high density of poly-
clonal heteroduplex smears was related to the abundance of
B-cell precursors at the same time points (Fig 2). Although
heteroduplex PCR analysis has a limited sensitivity (1±5%)
and cannot be used for MRD monitoring (Langerak et al,
1997), it is sufficiently sensitive to determine clonality in
samples containing high frequencies of `regenerating' B
cells. Thus, heteroduplex PCR analysis can be easily applied
to confirm the polyclonal origin of the precursor B cells in
regenerating BM.
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